Tuesday, September 22, 2026

Hello, FDA Put AI in a Warning Letter. We Need to Talk.


Greetings!


AI JUST BECAME A QUALITY ISSUE.


Not theoretically. Not someday.


FDA has now cited inappropriate use of AI in pharmaceutical manufacturing.


And that leaves Quality teams with a question that’s getting harder to ignore:

How much AI-generated work is already entering your Quality Unit?


And would your existing quality systems catch it?

SPECIAL WEBINAR ACCESS


$99

$0

YES. THIS ONE’S ON US.


Join the live webinar at no cost with promo code:

SAVE99

October 8 | 12-1 PM EST

LIVE • INTERACTIVE • INSTRUCTOR-LED

[REGISTER FOR $0]

THE WARNING LETTER WAS THE WAKE-UP CALL.


The bigger story is what happens next.


AI doesn’t necessarily arrive in a Quality Unit through some huge company-wide implementation.



It can show up much more quietly.

DOCUMENTATION

AI-assisted

drafting

REVIEW

AI-generated

summaries

DECISIONS

AI-supported

analysis

“SHADOW AI”

Tools being used

outside formal systems

The technology may be new. Your responsibility for the output isn’t.

This is about what happens when AI meets Quality.


🟠WHAT FDA ACTUALLY CITED

What made this warning letter different.


🟠WHERE “SHADOW AI” APPEARS

How AI can quietly enter otherwise well-run Quality Units.


🟠HOW TO THINK ABOUT AI RISK

Because different uses of AI create different considerations.



🟠WHETHER YOUR CONTROLS ARE READY

Document control. Attribution. Training. Validation. Review.

THIS CONVERSATION IS FOR YOU IF YOU WORK IN:

QA | QC | REGULATORY AFFAIRS | CMC | VALIDATION

ONE HOUR. ONE VERY TIMELY CONVERSATION.


$99 → $0

USE CODE SAVE99


October 8, 2026

12:00 PM - 1:00 PM EST


AI in the Quality Unit:

What FDA’s First AI Warning Letter Didn’t Tell You

Enter SAVE99 at registration to reduce your registration cost to $0.

Interested in this workshop?

Register today by calling our team at 416-628-7575 or email us at events@aapspharma.com

LinkedIn  Web

No comments:

Post a Comment